Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.
Roversi FM, Pericole FV, Machado-Neto JA, da Silva Santos Duarte A, Longhini AL, Corrocher FA, Palodetto B, Ferro KP, Rosa RG, Baratti MO, Verjovski-Almeida S, Traina F, Molinari A, Botta M, Saad ST. Roversi FM, et al. Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):450-461. doi: 10.1016/j.bbadis.2016.11.013. Epub 2016 Nov 11. Biochim Biophys Acta Mol Basis Dis. 2017. PMID: 27840303 Free article.
Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
Roversi FM, Cury NM, Lopes MR, Ferro KP, Machado-Neto JA, Alvarez MC, Dos Santos GP, Giardini Rosa R, Longhini AL, Duarte ADSS, Pericole FV, Favaro P, Yunes JA, Saad STO. Roversi FM, et al. Among authors: saad sto. J Cell Mol Med. 2019 Feb;23(2):1562-1571. doi: 10.1111/jcmm.14066. Epub 2018 Nov 28. J Cell Mol Med. 2019. PMID: 30484958 Free PMC article.
Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.
Roversi FM, Bueno MLP, da Silva JAF, Assis-Mendonça GR, Torello CO, Shiraishi RN, Pericole FV, Ferro KP, Duarte ASS, Rego EM, Saad STO. Roversi FM, et al. Among authors: saad sto. Cancer Immunol Immunother. 2022 Aug;71(8):1909-1921. doi: 10.1007/s00262-021-03111-2. Epub 2022 Jan 18. Cancer Immunol Immunother. 2022. PMID: 35039904 Free PMC article.
229 results